leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...187188189190191192193194195196197...235236»
  • ||||||||||  Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker:  Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) -  Sep 21, 2017   
    P2,  N=6, Active, not recruiting, 
    Recruiting --> Completed Recruiting --> Active, not recruiting | N=26 --> 6 | Trial primary completion date: Apr 2019 --> Mar 2017
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
    Enrollment change, Trial termination, Trial primary completion date:  FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) -  Sep 19, 2017   
    P2,  N=1, Terminated, 
    Trial primary completion date: Aug 2017 --> Aug 2019 N=25 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Sep 2017; Poor Accrual
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Trial primary completion date, Metastases:  Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer (clinicaltrials.gov) -  Sep 18, 2017   
    P2,  N=56, Active, not recruiting, 
    N=25 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Sep 2017; Poor Accrual Trial primary completion date: Sep 2017 --> Dec 2017
  • ||||||||||  Reolysin (pelareorep) / Oncolytics, Andrus Reo
    Trial primary completion date, Combination therapy, Metastases:  Study of REOLYSIN (clinicaltrials.gov) -  Sep 13, 2017   
    P1,  N=32, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2019 --> May 2017 Trial primary completion date: Oct 2017 --> Feb 2018
  • ||||||||||  sapitinib (AZD8931) / AstraZeneca
    Enrollment closed, Enrollment change, Combination therapy:  PANTHER: Phase I/II Trial of Antagonism of HER in GI Cancer (clinicaltrials.gov) -  Sep 11, 2017   
    P2,  N=24, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=60 --> 24
  • ||||||||||  BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
    Enrollment closed, Metastases:  INVICTAN (clinicaltrials.gov) -  Sep 6, 2017   
    P3,  N=120, Active, not recruiting, 
    Trial primary completion date: Aug 2017 --> Apr 2018 Recruiting --> Active, not recruiting
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date, Metastases:  mEGA: Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (clinicaltrials.gov) -  Sep 1, 2017   
    P=N/A,  N=13, Terminated, 
    Active, not recruiting --> Terminated | Trial primary completion date: May 2019 --> Aug 2017; Commercial reasons N=20 --> 13 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2016; Issues with recruitment.
  • ||||||||||  Biomarker, Enrollment change, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker:  MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) -  Sep 1, 2017   
    P2,  N=1400, Recruiting, 
    N=20 --> 13 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2016; Issues with recruitment. N=610 --> 1400 | Trial primary completion date: Feb 2019 --> Oct 2020
  • ||||||||||  oxaliplatin / Generic mfg.
    New P1/2 trial:  Lidocaine for Oxaliplatin-induced Neuropathy (clinicaltrials.gov) -  Aug 18, 2017   
    P1/2,  N=38, Recruiting, 
  • ||||||||||  palupiprant (AN0025) / Eisai, Adlai Nortye
    Enrollment open, Trial primary completion date, Combination therapy:  PRAER 1: Preoperative Radiotherapy and E7046 in Rectum Cancer (clinicaltrials.gov) -  Aug 15, 2017   
    P1b,  N=68, Recruiting, 
    Trial primary completion date: May 2017 --> Mar 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2019 --> Apr 2018